Valuation : CSL Limited

Market Cap 60.24B 51.84B 48.77B 44.55B 83.34B 5,688B 83.57B 576B 224B 2,918B 226B 221B 9,401B P/E 2027 *
20.6x
P/E 2028 * 18.7x
Enterprise Value 69.17B 59.52B 56B 51.16B 95.7B 6,531B 95.96B 662B 257B 3,351B 260B 254B 10,795B EV / Sales 2027 *
4.39x
EV / Sales 2028 * 4.21x
Free-Float
99.97%
Yield 2027 *
2.39%
Yield 2028 * 2.53%
1 day-0.57%
1 week+1.27%
Current month+1.71%
1 month+35.45%
3 months+88.47%
6 months+22.15%
Current year+1.07%
1 week 170.75
Extreme 170.75
177.39
1 month 130.8
Extreme 130.8
177.39
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Exercice

Director

152 0.0000%
8/21/26 Exercice

Director

244 0.0001%
8/21/26 Exercice

Director

-183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.57%+1.27%-17.24%-34.99% 60.48B
-1.87%+4.22%+45.93%-0.47% 84.22B
-2.23%+5.48%+499.46%+29.31% 59.43B
-2.03%-2.62%-7.46%+27.87% 50.31B
-4.58%-2.73%+2.93%+157.71% 48.91B
-1.64%+1.07%+57.80%-17.34% 33.17B
-0.98%+1.91%+48.35%+95.93% 25.95B
-0.19%-4.74%+2.30%+196.81% 22.78B
-1.13%-2.45%+65.99%+110.75% 16.73B
-0.76%-2.30%+44.40%+144.74% 14.74B
Average -1.47%-0.51%+74.25%+71.03% 41.67B
Weighted average by Cap. -1.65%+0.45%+89.42%+45.80%

Financials

2027 *2028 *
Net sales 15.76B 13.56B 12.76B 11.66B 21.81B 1,488B 21.87B 151B 58.51B 764B 59.19B 57.9B 2,460B 16.31B 14.04B 13.21B 12.06B 22.57B 1,540B 22.63B 156B 60.55B 790B 61.25B 59.91B 2,545B
Net income 2.84B 2.44B 2.3B 2.1B 3.93B 268B 3.94B 27.14B 10.53B 137B 10.65B 10.42B 443B 3.17B 2.72B 2.56B 2.34B 4.38B 299B 4.39B 30.29B 11.75B 153B 11.89B 11.63B 494B
Net Debt 8.93B 7.69B 7.23B 6.61B 12.36B 843B 12.39B 85.46B 33.16B 433B 33.54B 32.81B 1,394B 8.46B 7.28B 6.85B 6.26B 11.71B 799B 11.74B 80.98B 31.43B 410B 31.79B 31.09B 1,321B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-09-04 A$174.50 -0.57% 1,074,568
26-09-03 A$175.50 +0.95% 1,150,239
26-09-02 A$173.85 +0.89% 722,041
26-09-01 A$172.31 +0.43% 1,501,636
26-08-31 A$171.57 -0.44% 1,673,346
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
125.78USD
Average target price
122.21USD
Spread / Average Target
-2.84%

Quarterly revenue - Rate of surprise